Vincent Ribrag

19.5k citations
312 papers · 8.1k · 2 hit papers · h-index 47

Impact in

    • Lymphoma Diagnosis and Treatment
  • Oncology top 0.2%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Viral-associated cancers and disorders

Papers in

Vincent Ribrag

302 papers receiving 8.0k citations

Vincent Ribrag's Hit Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study 2018 · 462 citations
4620+3+6Years since publication200400600

Peers

Vincent Ribrag
Comparison fields: 5 of 106
  • Pathology and Forensic Medicine 3.4k
  • Oncology 4.0k
  • Genetics 1.5k
  • Hematology 860
  • Immunology 1.4k
Replace Lorenz Trümper with:
Lorenz Trümper Germany
Lisa M. Rimsza United States
Sonali M. Smith United States
Francesc Bosch Spain
Guillaume Cartron France
Kieron Dunleavy United States
Andres Forero‐Torres United States
Luca Baldini Italy
Yasuhiro Oki United States
Fredrick B. Hagemeister United States
Vincent Ribrag relative to Lorenz Trümper Germany Lorenz Trümper's profile →
Citations per field
00.5×2.9×
Lorenz Trümper · 1×
Citations per year

Countries citing papers authored by Vincent Ribrag

Since Specialization
Citations

This map shows the geographic impact of Vincent Ribrag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Ribrag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Ribrag more than expected).

Fields of papers citing papers by Vincent Ribrag

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Ribrag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Ribrag. The network helps show where Vincent Ribrag may publish in the future.

Co-authors

The 25 scholars most cited alongside Vincent Ribrag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vincent Ribrag Line = papers co-authored together Vincent Ribrag links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 312 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Hit paper breakdown →
2017702
2
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Hit paper breakdown →
2018462
3 2016242
4 2019229
5 2017219
6 2012189
7
Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.
1992162
8 2017152
9 2013143
10 2019132
11 2014124
12 2019119
13 2017115
14 2003110
15 2015108
16 2018108
17 2014100
18 201597
19 201789
20 201688

About Vincent Ribrag

Vincent Ribrag is a scholar working on Pathology and Forensic Medicine, Oncology, Molecular Biology, Genetics and Hematology, having authored 312 papers that have together received 8.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (171 papers), Chronic Lymphocytic Leukemia Research (63 papers), CAR-T cell therapy research (46 papers), Cancer Immunotherapy and Biomarkers (34 papers), Viral-associated cancers and disorders (33 papers), Protein Degradation and Inhibitors (26 papers), Multiple Myeloma Research and Treatments (24 papers) and CNS Lymphoma Diagnosis and Treatment (20 papers). The work is most often cited by research in Pathology and Forensic Medicine (3.4k citations), Oncology (4.0k citations), Genetics (1.5k citations), Hematology (860 citations) and Immunology (1.4k citations). Vincent Ribrag has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Jean‐Marie Michot, Pier Luigi Zinzani, Craig H. Moskowitz, Philippe Armand, Margaret A. Shipp, Arun Balakumaran, Pauline Brice, Bastian von Tresckow, John Radford and Jean‐Charles Soria. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer and Hematological Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact